A US court just put ownership of CRISPR back in play

A US court just put ownership of CRISPR back in play

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it.

Appeals court reopens the question of who owns patents for groundbreaking CRISPR discovery

The ruling does not invalidate the Broad's patents, but opens the door to relitigate who was first to show CRISPR could work in human cells

CRISPR patent spat revived by federal appeals court ruling

An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a revolutionary gene editing technology. The US Court of Appeals for the Federal ...

The Standard for Conception: Don't Ask "Will it Work"

by Dennis Crouch In an interesting decision affecting one of the most high-profile patent disputes in biotechnology, the Federal Circuit has partially vacated and remanded a PTAB decision that awarded priority of invention for CRISPR-Cas9 technology in eukaryotic cells to scientists at the Broad Institute. Regents of the University of California v. Broad Institute, Inc., Nos. 2022-1594, 2022-1653 (Fed. Cir. May 12, 2025). The court determined th…

Brussels – Last Tuesday in Brussels, the decisive negotiations on the future of the so-called new genetic engineering (NGT) in Europe began. In the so-called trilogue, the European Commission, the Council and the Parliament are negotiating on a possible relaxation of the existing genetic engineering rules – and thus on nothing less than the decision-making process for agriculture, food and consumer protection over the next few decades. Critic [.…

The EU is currently negotiating in the trialogue to deregulate genetic engineering legislation - which a new legal opinion says about it.